Teligent Announces FDA Approval of Halobetasol Propionate Ointment, 0.05%

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application from the U.S. Food and Drug Administration (FDA) of Halobetasol Propionate Ointment, 0.05%. This is Teligent’s second approval for 2018, and its twenty-first approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

As quoted in the press release:

“Halobetasol Propionate Ointment, 0.05% is Teligent’s second FDA approval in 2018,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “This approval was received fifteen months from the filing date and shows Teligent’s commitment to execution regarding our high-value pipeline. We expect to launch this product in the second quarter of 2018.”

Mr. Grenfell-Gardner continued, “We now have twenty-six topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

Click here to read the full press release.